BioVaxys Technology Corp, a Canadian biotechnology company, has recently reported promising results from a Phase 1 clinical study targeting women with hormone-receptor positive/HER2-negative breast cancer. This announcement, made on December 17, 2025, highlights the company’s ongoing commitment to developing innovative immunotherapy solutions for cancer treatment.
BioVaxys Technology Corp, incorporated in 2001, is headquartered in Vancouver, British Columbia, Canada. The company specializes in the development of vaccines and immunotherapy products, focusing on addressing global health challenges, particularly in the realms of infectious diseases and cancer. Its mission is to revolutionize the treatment and prevention of infectious diseases and to pioneer new immunotherapy approaches for cancer.
One of the company’s flagship products is VaxMite, a novel vaccine under development aimed at protecting against Plasmodium falciparum, the most lethal form of malaria. In addition to its work on malaria, BioVaxys is exploring the potential applications of its technology platform across various medical and healthcare domains.
Despite the positive news from the clinical study, BioVaxys Technology Corp’s financial metrics reflect a challenging period. As of December 23, 2025, the company’s stock closed at $0.24 CAD, within a 52-week trading range of $0.17 to $0.70 CAD. The company’s valuation metrics are currently negative, with a price-to-earnings ratio of -1.20 and a price-to-book ratio of -2.91. These figures indicate that BioVaxys is operating at a loss relative to its equity base.
The company’s market capitalization stands at 10,180,000 CAD, reflecting its current financial standing on the Canadian National Stock Exchange. As of the latest reports, no further corporate developments have been announced since the December 17 release.
BioVaxys Technology Corp continues to focus on its research and development efforts, aiming to bring innovative solutions to the forefront of global health challenges. The positive results from the Phase 1 clinical study represent a significant step forward in the company’s mission to develop new immunotherapy approaches for cancer treatment.
